{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Humans&page=32",
    "query": {
      "condition": "Healthy Humans",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 1466,
    "total_pages": 147,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Humans&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Humans&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T03:23:04.801Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00963157",
      "title": "Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 789,
      "start_date": "2009-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-12-24",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 7,
      "location_summary": "Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963157"
    },
    {
      "nct_id": "NCT06698926",
      "title": "A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "ABBV-CLS-616",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 110,
      "start_date": "2024-11-11",
      "completion_date": "2026-01-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698926"
    },
    {
      "nct_id": "NCT07300085",
      "title": "A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Fluzone® High-Dose (HD) influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-1406 Injection",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 710,
      "start_date": "2025-11-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07300085"
    },
    {
      "nct_id": "NCT02743117",
      "title": "Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Monovalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 301,
      "start_date": "2016-05-02",
      "completion_date": "2016-11-30",
      "has_results": true,
      "last_update_posted_date": "2017-10-04",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida • Stockbridge, Georgia • Portland, Oregon",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02743117"
    },
    {
      "nct_id": "NCT05945485",
      "title": "A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "DCVC H1 HA mRNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Seasonal Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-10-16",
      "completion_date": "2026-05-21",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05945485"
    },
    {
      "nct_id": "NCT02859259",
      "title": "A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "BMS-663068 (1 tablet at 600 mg)",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 (4 tablets at 150 mg each tablet)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2016-08-12",
      "completion_date": "2016-08-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859259"
    },
    {
      "nct_id": "NCT07593859",
      "title": "Overcoming the Barriers to Effective Transcranial Temporal Interference Stimulation in Humans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Adult Participants"
      ],
      "interventions": [
        {
          "name": "transcranial Temporal Interference Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Northeastern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-02-01",
      "completion_date": "2029-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07593859"
    },
    {
      "nct_id": "NCT06225115",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cognitive Dysfunction",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "KYN-5356",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kynexis B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2023-12-21",
      "completion_date": "2024-10-07",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06225115"
    },
    {
      "nct_id": "NCT05048875",
      "title": "An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Cohort 1 - Group 1 JNJ High Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 2 JNJ Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 2 JNJ Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 1/2 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-02-03",
      "completion_date": "2024-09-10",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05048875"
    },
    {
      "nct_id": "NCT00853554",
      "title": "Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Hydromorphone Hydrochloride tablet 8 mg",
          "type": "DRUG"
        },
        {
          "name": "Dilaudid® tablet 8 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2002-12",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-10-23T03:23:04.801Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853554"
    }
  ]
}